BIOCARTIS

Company Overview

Biocartis is a global molecular diagnostics company that offers proprietary oncology test panels and services for pharma clients in the development of specific diagnostic tests. The company has developed its proprietary Idylla platform, which is a fully automated, sample-to-result, real-time PCR system that offers accurate, reliable molecular information from virtually any biological sample. The platform is an all-in-one platform; all consumables required to perform sample preparation and RT-PCR amplification and detection are provided in a single cartridge that is loaded into the Idylla system.

The company has developed specific CE-IVD oncology and infectious disease assays for use with the Idylla platform. Some of these include BRAF Mutation Test, EGFR Mutation Test, ctKRAS Mutation Test, MSI Test, NRAS-BRAF Mutation Test and ctNRAS-BRAF Mutation Test, among others. Idylla offers tests for melanoma, colorectal and lung cancer.

Biocartis also offers similar assays in the RUO category. In the infectious disease category, Biocartis has developed and offers the Idylla SARS-CoV-2 Test for the diagnosis of COVID-19 antigen and the SeptiCyte RAPID host response test that helps to distinguish sepsis from non-infectious systemic inflammation.

Company's Business Segments

• Molecular Diagnostics : The company specialises in molecular diagnostics through platforms like the IDYLLA Platform and other oncology and infectious disease tests. IDYLLA Platform: All-in-one modular solution for oncology tests, including Software, Workflow, Detection and analysis kit. Oncology tests: Invitro diagnostic tests include ColoNode, HepatoPredict, Merlin Assay, Idylla Genefusion panel, KRAS mutation test, NRAS-BRAF mutation test and MSI test